Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Nov;37(11):2307–2310. doi: 10.1128/aac.37.11.2307

Efficacy of itraconazole solution in a rabbit model of invasive aspergillosis.

T F Patterson 1, A W Fothergill 1, M G Rinaldi 1
PMCID: PMC192383  PMID: 8285610

Abstract

The efficacy of an itraconazole-cyclodextrin solution against Aspergillus fumigatus was assessed in an immunosuppressed, temporarily leukopenic rabbit model of invasive aspergillosis and compared with that of amphotericin B. Oral itraconazole solution at dosages of 20 and 40 mg/kg/day improved survival as compared with that of controls. Itraconazole (40 mg/kg/day) not only improved survival and reduced antigen levels but also significantly eradicated A. fumigatus from tissues and was as effective as amphotericin B in these studies. The higher dose of itraconazole produced higher levels in serum, which correlated with improved efficacy of the drug. This itraconazole-cyclodextrin solution was well absorbed and was effective in the treatment of experimental invasive aspergillosis; it demonstrates the potential of this class of agents in improving therapy for invasive aspergillosis.

Full text

PDF
2307

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bodet C. A., 3rd, Jorgensen J. H., Drutz D. J. Simplified bioassay method for measurement of flucytosine or ketoconazole. J Clin Microbiol. 1985 Aug;22(2):157–160. doi: 10.1128/jcm.22.2.157-160.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bodey G. P., Vartivarian S. Aspergillosis. Eur J Clin Microbiol Infect Dis. 1989 May;8(5):413–437. doi: 10.1007/BF01964057. [DOI] [PubMed] [Google Scholar]
  3. Denning D. W., Hanson L. H., Perlman A. M., Stevens D. A. In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn Microbiol Infect Dis. 1992 Jan;15(1):21–34. doi: 10.1016/0732-8893(92)90053-v. [DOI] [PubMed] [Google Scholar]
  4. Denning D. W., Stepan D. E., Blume K. G., Stevens D. A. Control of invasive pulmonary aspergillosis with oral itraconazole in a bone marrow transplant patient. J Infect. 1992 Jan;24(1):73–79. doi: 10.1016/0163-4453(92)91066-k. [DOI] [PubMed] [Google Scholar]
  5. Denning D. W., Stevens D. A. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis. 1990 Nov-Dec;12(6):1147–1201. doi: 10.1093/clinids/12.6.1147. [DOI] [PubMed] [Google Scholar]
  6. Denning D. W., Tucker R. M., Hanson L. H., Stevens D. A. Treatment of invasive aspergillosis with itraconazole. Am J Med. 1989 Jun;86(6 Pt 2):791–800. doi: 10.1016/0002-9343(89)90475-0. [DOI] [PubMed] [Google Scholar]
  7. Graybill J. R., Kaster S. R. Experimental murine aspergillosis. Comparison of amphotericin B and a new polyene antifungal drug, SCH 28191. Am Rev Respir Dis. 1984 Feb;129(2):292–295. [PubMed] [Google Scholar]
  8. Graybill J. R. New antifungal agents. Eur J Clin Microbiol Infect Dis. 1989 May;8(5):402–412. doi: 10.1007/BF01964056. [DOI] [PubMed] [Google Scholar]
  9. Hostetler J. S., Hanson L. H., Stevens D. A. Effect of cyclodextrin on the pharmacology of antifungal oral azoles. Antimicrob Agents Chemother. 1992 Feb;36(2):477–480. doi: 10.1128/aac.36.2.477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Longman L. P., Martin M. V. A comparison of the efficacy of itraconazole, amphotericin B and 5-fluorocytosine in the treatment of Aspergillus fumigatus endocarditis in the rabbit. J Antimicrob Chemother. 1987 Nov;20(5):719–724. doi: 10.1093/jac/20.5.719. [DOI] [PubMed] [Google Scholar]
  11. Patterson T. F., George D., Miniter P., Andriole V. T. Saperconazole therapy in a rabbit model of invasive aspergillosis. Antimicrob Agents Chemother. 1992 Dec;36(12):2681–2685. doi: 10.1128/aac.36.12.2681. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Patterson T. F., George D., Miniter P., Andriole V. T. The role of fluconazole in the early treatment and prophylaxis of experimental invasive aspergillosis. J Infect Dis. 1991 Sep;164(3):575–580. doi: 10.1093/infdis/164.3.575. [DOI] [PubMed] [Google Scholar]
  13. Patterson T. F., Miniter P., Dijkstra J., Szoka F. C., Jr, Ryan J. L., Andriole V. T. Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes. J Infect Dis. 1989 Apr;159(4):717–724. doi: 10.1093/infdis/159.4.717. [DOI] [PubMed] [Google Scholar]
  14. Patterson T. F., Miniter P., Ryan J. L., Andriole V. T. Effect of immunosuppression and amphotericin B on Aspergillus antigenemia in an experimental model. J Infect Dis. 1988 Aug;158(2):415–422. doi: 10.1093/infdis/158.2.415. [DOI] [PubMed] [Google Scholar]
  15. Polak A. Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice. Chemotherapy. 1987;33(5):381–395. doi: 10.1159/000238524. [DOI] [PubMed] [Google Scholar]
  16. Sabetta J. R., Miniter P., Andriole V. T. The diagnosis of invasive aspergillosis by an enzyme-linked immunosorbent assay for circulating antigen. J Infect Dis. 1985 Nov;152(5):946–953. doi: 10.1093/infdis/152.5.946. [DOI] [PubMed] [Google Scholar]
  17. Schmitt H. J., Edwards F., Andrade J., Niki Y., Armstrong D. Comparison of azoles against aspergilli in vitro and in an experimental model of pulmonary aspergillosis. Chemotherapy. 1992;38(2):118–126. doi: 10.1159/000238951. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES